接受PRRT的神经内分泌肿瘤患者肿瘤-血池比值变化作为无进展生存期和总生存期的预后标志物
在埃森大学医院核医学科接受≥2周期PRRT并有基线和随访SSTR-PET的神经内分泌肿瘤患者中,基线TBR处于第1四分位者PFS为14.4个月、OS为32.5个月,分别短于第3、4四分位及第2、3、4四分位;校正RECIST缓解等预后因素后,TBR自基线至随访升高与更短PFS(HR=2.91,95%CI=1.54-5.50,p=0.01)和更短OS(HR=1.64,95%CI=1.03-2.62,p=0.04)独立相关,而SUVmean变化与PFS、OS无关联。
要点
- 基线TBR第1四分位者PFS为14.4个月,分别短于第3四分位23.7个月(p=0.03)和第4四分位24.1个月(p=0.02)。
- 基线TBR第1四分位者OS为32.5个月,分别短于第2四分位41.8个月(p=0.03)、第3四分位69.2个月(p<0.01)和第4四分位42.7个月(p=0.03)。
- 校正RECIST缓解等预后标志后,TBR自基线升高与更短PFS(HR=2.91,95%CI=1.54-5.50,p=0.01)和更短OS(HR=1.64,95%CI=1.03-2.62,p=0.04)独立相关。
核心结论
- 基线TBR及TBR变化均与PFS和OS显著相关,可能改善患者选择和形态学缓解评估。
- 未来试验需评估TBR在PRRT期间治疗监测中的作用,并前瞻性探索TBR作为患者选择的预测标志物。
研究设计与样本
- 检索埃森大学医院核医学科机构数据库,纳入接受≥2周期PRRT且有基线和随访SSTR-PET的神经内分泌肿瘤患者。
- 由两名设盲独立阅片者报告新发病灶,采用SUV和TBR量化每例患者最多9个病灶的肿瘤摄取。
- 采用Cox回归模型和log-rank检验分析基线TBR及摄取变化/新发病灶与PFS和OS的关联。
主要发现
- 基线TBR第1四分位者PFS为14.4个月,短于第3四分位23.7个月(p=0.03)和第4四分位24.1个月(p=0.02)。
- 基线TBR第1四分位者OS为32.5个月,短于第2四分位41.8个月(p=0.03)、第3四分位69.2个月(p<0.01)和第4四分位42.7个月(p=0.03)。
- 校正RECIST缓解等预后标志后,基线至随访TBR升高与更短PFS独立相关(HR=2.91,95%CI=1.54-5.50,p=0.01),并与更短OS独立相关(HR=1.64,95%CI=1.03-2.62,p=0.04)。
- SUVmean变化与PFS或OS无关联。
关键数值与推荐
- 原文未报告基于SSTR-PET的PRRT患者选择标准。
临床怎么用
- 作者认为基线TBR及TBR变化与PFS和OS显著相关,可能改善患者选择和形态学缓解评估。
- 作者指出未来试验需评估TBR在PRRT期间治疗监测中的作用,并前瞻性探索TBR作为患者选择的预测标志物。
局限性
- 原文结论指出未来试验需评估TBR在PRRT期间治疗监测中的作用,并前瞻性探索TBR作为患者选择的预测标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Historically, patient selection for peptide receptor radionuclide therapy (PRRT) has been performed by virtue of somatostatin receptor scintigraphy (SRS). In recent years, somatostatin receptor positron emission tomography (SSTR-PET) has gradually replaced SRS because of its improved diagnostic capacity, creating an unmet need for SSTR-PET-based selection criteria for PRRT. Tumor-to-blood ratio (TBR) measurements have shown high correlation with the net influx rate Ki, reflecting the tumor somatostatin receptor expression, to a higher degree than standardized uptake value (SUV) measurements. TBR may therefore predict treatment response to PRRT. In addition, changes in semiquantitative SSTR-PET parameters have been shown to predate morphological changes, making them a suitable metric for response assessment. METHODS: The institutional database of the Department of Nuclear Medicine (University Hospital Essen) was searched for NET patients undergoing ≥ 2 PRRT cycles with available baseline and follow-up SSTR-PET. Two blinded independent readers reported the occurrence of new lesions quantified tumor uptake of up to nine lesions per patient using SUV and TBR. The association between baseline TBR and changes in uptake/occurrence of new lesions with progression-free survival (PFS) and overall survival (OS) was tested by use of a Cox regression model and log-rank test. RESULTS: Patients with baseline TBR in the 1st quartile had a shorter PFS (14.4 months) than those in the 3rd (23.7 months; p = 0.03) and 4th (24.1 months; p = 0.02) quartile. Similarly, these patients had significantly shorter OS (32.5 months) than those with baseline TBR in the 2nd (41.8 months; p = 0.03), 3rd (69.2 months; p < 0.01), and 4th (42.7 months; p = 0.03) quartile. Baseline to follow-up increases in TBR were independently associated with shorter PFS when accounting for prognostic markers, e.g., RECIST response (hazard ratio = 2.91 [95%CI = 1.54-5.50]; p = 0.01). This was confirmed with regard to OS (hazard ratio = 1.64 [95%CI = 1.03-2.62]; p = 0.04). Changes in SUVmean were not associated with PFS or OS. CONCLUSIONS: Baseline TBR as well as changes in TBR were significantly associated with PFS and OS and may improve patient selection and morphological response assessment. Future trials need to assess the role of TBR for therapy monitoring also during PRRT and prospectively explore TBR as a predictive marker for patient selection.
引用
- Weber M, Pettersson O, Seifert R, et al. Changes in tumor-to-blood ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT. Eur J Nucl Med Mol Imaging. 2023. PMID: 37947848. doi:10.1007/s00259-023-06502-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。